Kestra Medical Technologies (KMTS) Cost of Revenue (2024 - 2026)

Kestra Medical Technologies (KMTS) has 3 years of Cost of Revenue data on file, last reported at $11.6 million in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $11.6 million, up 36.32% year-over-year; the trailing twelve-month figure through Jan 2026 was $42.9 million (up 23.79% YoY), and the FY2025 annual result was $35.6 million, up 29.7% from the prior year.
• Cost of Revenue advanced to $11.6 million in Q1 2026 per KMTS's latest filing, from $11.1 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $11.6 million in Q1 2026 and troughed at $7.4 million in Q1 2024.
• A 3-year average of $9.4 million and a median of $8.9 million in 2024 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2025 and 2026: Cost of Revenue increased 10.89% in 2025, then jumped 36.32% in 2026.
• A 3-year view of Cost of Revenue shows it stood at $8.9 million in 2024, then climbed by 25.46% to $11.1 million in 2025, then increased by 4.53% to $11.6 million in 2026.
• Business Quant data shows KMTS's Cost of Revenue at $11.6 million in Q1 2026, $11.1 million in Q4 2025, and $10.5 million in Q3 2025.